Digest Network Come funziona
Network
/
Società
En
Non verificato

Enveric Biosciences

Di cosa scriviamo

BiotecnologiaFarmaceuticaPsichiatriaSaluteSanità

58 comunicati stampa

Guarda tutti i comunicati
09/06/2026
Eventi
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
Fonte
Enveric Biosciences
Emittente
Business Wire
1.00
0
02/06/2026
Psichiatria
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
Fonte
Enveric Biosciences
Emittente
Business Wire
1.00
0
19/05/2026
Industria
Psichiatria
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
Fonte
Enveric Biosciences
Emittente
Business Wire
1.00
0
15/05/2026
Mercato azionario
Psichiatria
Scienza
Biotecnologia
Salute
Farmaceutica
Sanità
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Fonte
Enveric Biosciences
Emittente
Business Wire
1.00
0
13/05/2026
Industria
Biotecnologia
Sanità
Psichiatria
Salute
Farmaceutica
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
Fonte
Enveric Biosciences
Emittente
Business Wire
1.00
0
05/05/2026
Industria
Psichiatria
Scienza
Biotecnologia
Medicina alternativa
Salute
Farmaceutica
Sanità
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
Fonte
Enveric Biosciences
Emittente
Business Wire
1.00
0
21/04/2026
Eventi
Biotecnologia
Salute
Psichiatria
Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum
Fonte
Enveric Biosciences
Emittente
Business Wire
1.00
0
31/03/2026
Industria
Psichiatria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
Fonte
Enveric Biosciences
Emittente
Business Wire
1.00
0
27/03/2026
Mercato azionario
Psichiatria
Scienza
Biotecnologia
Salute
Farmaceutica
Sanità
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
Fonte
Enveric Biosciences
Emittente
Business Wire
1.00
0
25/02/2026
Legge/Diritto
Biotecnologia
Farmaceutica
Sanità
Salute
Psichiatria
Associazioni/Professionisti
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
Fonte
Enveric Biosciences
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0